Inspiration Biopharmaceuticals names John Butler as ceo

Replaces Michael Griffith who takes position of cso

Inspiration Biopharmaceuticals, a US biopharmaceutical company focused on the development of treatments haemophilia, has appointed John Butler as ceo. He has replaced Michael Griffith, who has become chief scientific officer and remains company president.

Butler has joined Inspiration from Genzyme, which was acquired by Sanofi in April. While at Genzyme, he was most recently president of the company's rare genetic diseases business. He also led the company's renal, endocrinology, and cardiovascular businesses.

Prior to Genzyme, Butler held sales and marketing positions at Amgen and Hoffmann-La Roche.

You may also like

Manufacturing

CMC Biologics and Inspiration agree supply of IB1001

For the treatment and prevention of bleeding in haemophilia B patients
Pharmaceutical
OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT has launched two IVDR-certified prenatal FISH probe kits as it begins transitioning its full CytoCell portfolio ahead of the EU’s 2028 Class C deadline
Pharmaceutical
CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
Packaging
Designing the future of pharma packaging – in Europe

Designing the future of pharma packaging – in Europe

Are you thinking about sustainable pharmaceutical packaging? ACG is committed to advancing sustainability in pharmaceutical packaging
Pharmaceutical
Reconstitutable powder filling system for global MedTech client

Reconstitutable powder filling system for global MedTech client

3P innovation's custom automation expertise enables customers to advance product and process innovation across diverse industries
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Pharmaceutical
Formulation freedom in clinical development: Why Fill2Weight matters

Formulation freedom in clinical development: Why Fill2Weight matters

As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Subscribe now